By CEA Registry Team on
3/28/2011 5:34 PM
REMS has given the FDA and life-science companies a tool to create risk-management programs spurring innovation while addressing safety concerns. How generic manufacturers address the regulatory and economic challenges posed by REMS will provide interesting case studies in the months and years ahead.
by: Michael J. Cangelosi
Please view the blog archive for earlier entries